EMA Recommends First EU Vaccine Against Swine Dysentery, Targeting Disease with 30-50% Mortality Rate
Key Insights
The European Medicines Agency (search) has issued a positive opinion for Biobhyo (search), the first vaccine authorized in the EU to protect pigs against swine dysentery (search) disease.
Swine dysentery (search) affects up to 90% of pigs in infected herds with a mortality rate of 30-50%, caused by the bacterium Brachyspira hyodysenteriae (search).
Clinical studies demonstrated vaccine efficacy when administered at five and eight weeks of age, showing reduced incidence of dysenteric diarrhea (search) in commercial farm settings.
The European Medicines Agency (search) (EMA) has issued a positive opinion for the approval of Biobhyo (search), marking a significant milestone as the first vaccine authorized in the European Union to protect pigs against swine dysentery (search) disease. No vaccine is currently authorized in the EU against this highly infectious gastrointestinal condition that poses substantial challenges to veterinarians and farmers worldwide.
Disease Impact and Unmet Medical Need
Swine dysentery (search) represents a critical veterinary health challenge, caused by the bacterium Brachyspira hyodysenteriae (search). The disease demonstrates severe impact on pig populations, affecting up to 90% of pigs in infected herds with a mortality rate ranging from 30-50%. This infectious condition causes dysenteric diarrhea (search) in pigs, significantly impacting both animal welfare and farm productivity across affected operations.
Vaccine Composition and Mechanism
Biobhyo (search) contains an inactivated strain of Brachyspira hyodysenteriae (search) combined with an adjuvant designed to stimulate immune response. The vaccine is formulated as a ready-to-use emulsion for injection, providing a practical administration method for veterinary use in pig populations.
Clinical Efficacy Demonstration
The vaccine's efficacy was evaluated through two comprehensive studies that compared the incidence of dysenteric diarrhea (search) in vaccinated versus non-vaccinated pigs across commercial farms in two different European countries. The vaccination protocol involves administering the first dose at five weeks of age, followed by a second dose at eight weeks of age. This two-dose regimen demonstrated a reduction in dysenteric diarrhea caused by Brachyspira hyodysenteriae (search) in the studied pig populations.
Safety Assessment
Based on the comprehensive risk assessment conducted as part of the evaluation process for all veterinary products, Biobhyo (search) is not expected to pose risks to human health, animal health, or environmental safety when used according to the product information guidelines.
Regulatory Pathway Forward
The positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP) will now advance to the European Commission for adoption of decisions regarding EU-wide marketing authorization of the vaccine. This regulatory milestone represents the culmination of the scientific evaluation process and positions the vaccine for potential commercial availability across European markets.